Vaccine major Serum Institute of India has acquired 20 per cent stake in medical device company IntegriMedical to advance needle-free injection technology, for an undisclosed amount. The technology addresses needle-phobic patients, helping increase patient compliance, reduce needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion, a note from the company said. Serum Institute of India (SII) has been investing in backend companies and had in August 2021, bought out the Indian partner in SCHOTT Kaisha, securing its supplies of pharma packaging products, including vials, syringes, ampoules and cartridges used to package life-saving medication. IntegriMedical has developed a US patented needle-free injection system (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs, the note said. N-FIS will be available in the Indian private market, offering patient